Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company specializing in Antibody Drug Conjugates (ADCs), announced that shareholders approved all management proposals with a large majority at the ordinary virtual Annual General Meeting held on June 23, 2026. The approval rates ranged between 98.67% and 98.72%, reflecting strong shareholder support for the company's strategic direction.
Key resolutions passed include the formal approval of the actions of the Management Board and Supervisory Board for the 2024/2025 financial year, the appointment of auditors for the 2025/2026 financial year, and the approval of the remuneration report for the Management Board. Shareholders also elected Mr. Jack Yefei Ling as a new member of the Supervisory Board, and approved an amendment to the Articles of Association reducing the size of the Supervisory Board from seven to five members. Attendance, including postal votes, reached 80.55% of the current capital stock.
This annual meeting is a critical event for Heidelberg Pharma, as it validates the company's governance and strategic initiatives. The election of Jack Yefei Ling brings fresh perspective to the Supervisory Board, which now consists of five members. The reduction in board size could streamline decision-making processes, potentially accelerating the development of the company's innovative ADC pipeline.
Heidelberg Pharma is pioneering cancer therapies using Amanitin, a toxin derived from the green death cap mushroom, through its proprietary ATAC technology. The lead candidate, HDP-101 (INN: pamlectabart tismanitin), targets BCMA for multiple myeloma and has received Orphan Drug Designation and Fast Track Designation from the FDA. Other candidates include HDP-102 for Non-Hodgkin Lymphoma in clinical development, and HDP-103 and HDP-104 for metastatic castration-resistant prostate cancer and gastrointestinal tumors, respectively, which have completed preclinical development and are available for partnering.
The implications of these shareholder approvals are significant for the biotech industry and patients. With strong governance support, Heidelberg Pharma can advance its clinical programs, potentially bringing novel therapies to market for cancers with high unmet medical needs. The company's unique Amanitin-based approach offers a new therapeutic modality that could differentiate it from other ADC developers. For investors, the high approval rates and board restructuring signal confidence in the company's leadership and strategy, which may influence market perception and future collaborations.
For more details on the Annual General Meeting and voting results, visit https://heidelberg-pharma.com/en/agm. Additional company information is available at www.heidelberg-pharma.com.
